Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for the reproxalap New Drug Application (NDA) for the treatment of dry eye disease. The extended PDUFA target action date is March 16, 2026
https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-announces-pdufa-extension-new-drug
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.